We have observed
10 EP applications
has served for within the last five+ years.
(We consider all applications which have an EP A1 or A2 publication dated after October 21, 2013).
Please note, that we only count EP applications,
in which the name of the patent attorney is explicitly mentioned as representative.
These EP applications are:
CANINE BABESIOSIS VACCINE ANTIGEN
AN AQUEOUS COMPOSITION COMPRISING A BIOLOGICAL ANTIGEN AND AN ACRYLIC ACID POLYMER
RECOMBINANT NONPATHOGENIC MDV VECTOR PROVIDING MULTIVALENT IMMUNITY
RECOMBINANT NON-PATHOGENIC MAREK'S DISEASE VIRUS CONSTRUCTS ENCODING INFECTIOUS LARYNGOTRACHEITIS VIRUS AND NEWCASTLE DISEASE VIRUS ANTIGENS
AN IMMUNOGENIC COMPOSITION OF KILLED LEPTOSPIRA BACTERIA
LIQUID STABLE VIRUS VACCINES